

NEUROENDOCRINE
DISEASE ORIENTED GROUP

AGENDA

OPEN SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 29th, 2017

TIME: 13:00 – 13:45

CHAIRS: DR. TIM ASMIS & DR. SIMRON SINGH

- 13:00 WELCOME AND INTRODUCTION **DR. T. ASMIS**
- 13:00 ACTIVE TRIALS FOR UPDATE/DISCUSSION
- NEC.3 (ALLIANCE 021202):** PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB
VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS **DR. T. ASMIS**
- 13:05 NEW CONCEPTS IN DEVELOPMENT
- A021602:** RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB
VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS
AFTER PROGRESSION ON EVEROLIMUS STUDY **DR. T. ASMIS**
- A021602:** CANADIAN CONTENT – FINANCIAL TOXICITY **DR. T. ASMIS**
- TEMPT STUDY:** TEMOZOLOMIDE AND PEMBROLIZUMAB TOGETHER TO
INCREASE IMMUNOGENICITY OF ADVANCED PANCREATIC NEUROENDOCRINE
TUMOURS **DR. T. ASMIS**
- 13:30 INTERGROUP TASK FORCE UPDATE **DR. T. ASMIS**
- 13:40 COMMNETS – COMMONWEALTH NEUROENDOCRINE TUMOUR COLLABORATION **DR. T. ASMIS**
- 13:45 CLOSING REMARKS